SG3 Management’s Iovance Biotherapeutics IOVA Stock Holding History

SG3 Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-90,000	Closed	-$575K	–	93
2022 Q4	$575K	Buy	+90,000	New	+$703K	0.08%	109
2021 Q4	–	Sell	-75,000	Closed	-$1.85M	–	1156
2021 Q3	$1.85M	Buy	+75,000	New	+$1.77M	0.06%	321
2021 Q1	–	Sell	-128,000	Closed	-$5.94M	–	1330
2020 Q4	$5.94M	Sell	128,000 -50,000	-28%	-$1.99M	0.11%	167
2020 Q3	$5.86M	Buy	+178,000	New	+$5.46M	0.22%	111

Other funds holding IOVA

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SG3 Management's IOVA Position: Q1 2023 in Review

SG3 Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2023, closing a stake of 67,000 shares — an estimated $428K sold.

SG3 Management first reported a position in IOVA in Q4 2021 and held it in 2 quarters. The position peaked at $428K in Q4 2022. 228 funds tracked by Wall St. Rank hold IOVA as of Q1 2023.

SG3 Management reported no remaining Iovance Biotherapeutics position as of Q1 2023 after selling out during the quarter.
SG3 Management sold 67,000 Iovance Biotherapeutics shares in Q1 2023, an estimated $428K.
SG3 Management first reported a position in Iovance Biotherapeutics in Q4 2021 and held it in 2 quarters.
SG3 Management's Iovance Biotherapeutics position peaked at $428K in Q4 2022.
228 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2023.

Based on SG3 Management's 13F filing for Q1 2023, filed 15 May 2023.